Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 7,500 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph Lyssikatos sold 7,500 shares of the business’s stock in a transaction dated Thursday, August 21st. The shares were sold at an average price of $20.01, for a total transaction of $150,075.00. Following the completion of the transaction, the insider directly owned 940,188 shares of the company’s stock, valued at $18,813,161.88. The trade was a 0.79% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Enliven Therapeutics Trading Up 5.1%

Shares of ELVN stock opened at $20.85 on Friday. The firm has a 50-day moving average price of $20.61 and a 200 day moving average price of $19.85. Enliven Therapeutics, Inc. has a twelve month low of $13.30 and a twelve month high of $30.03. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -10.43 and a beta of 0.93.

Enliven Therapeutics (NASDAQ:ELVN) last announced its earnings results on Wednesday, August 13th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.04. As a group, research analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Institutional Investors Weigh In On Enliven Therapeutics

Several hedge funds have recently modified their holdings of ELVN. Tower Research Capital LLC TRC boosted its position in shares of Enliven Therapeutics by 230.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock worth $36,000 after acquiring an additional 1,114 shares during the last quarter. GAMMA Investing LLC raised its holdings in Enliven Therapeutics by 3,058.1% in the first quarter. GAMMA Investing LLC now owns 2,716 shares of the company’s stock valued at $53,000 after buying an additional 2,630 shares during the period. Quantbot Technologies LP purchased a new position in Enliven Therapeutics in the first quarter valued at approximately $60,000. BNP Paribas Financial Markets raised its holdings in Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after buying an additional 930 shares during the period. Finally, Tower Research Capital LLC TRC raised its holdings in Enliven Therapeutics by 194.3% in the second quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock valued at $106,000 after buying an additional 3,490 shares during the period. 95.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Robert W. Baird boosted their target price on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the company an “outperform” rating in a research note on Monday, June 16th. Jones Trading decreased their target price on shares of Enliven Therapeutics from $36.00 to $27.00 and set a “buy” rating on the stock in a research report on Friday, May 16th. The Goldman Sachs Group started coverage on shares of Enliven Therapeutics in a research report on Monday, June 16th. They issued a “buy” rating and a $37.00 target price on the stock. Finally, HC Wainwright raised their target price on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the stock a “buy” rating in a research report on Wednesday, July 2nd. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $41.20.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.